Generate Investment Management Ltd Purchases 22,330 Shares of Cencora, Inc. (NYSE:COR)

Generate Investment Management Ltd grew its holdings in Cencora, Inc. (NYSE:COR) by 92.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 46,508 shares of the company’s stock after purchasing an additional 22,330 shares during the quarter. Generate Investment Management Ltd’s holdings in Cencora were worth $10,449,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of COR. Livforsakringsbolaget Skandia Omsesidigt grew its holdings in Cencora by 4.4% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,575 shares of the company’s stock worth $6,420,000 after acquiring an additional 1,200 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in shares of Cencora by 1.1% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 28,597 shares of the company’s stock worth $6,425,000 after purchasing an additional 312 shares during the last quarter. Ledyard National Bank grew its stake in shares of Cencora by 64.2% during the fourth quarter. Ledyard National Bank now owns 7,822 shares of the company’s stock worth $1,757,000 after purchasing an additional 3,058 shares during the period. Trilogy Capital Inc. increased its holdings in Cencora by 5.1% in the fourth quarter. Trilogy Capital Inc. now owns 1,038 shares of the company’s stock valued at $233,000 after purchasing an additional 50 shares during the last quarter. Finally, Choreo LLC lifted its stake in Cencora by 1.6% in the fourth quarter. Choreo LLC now owns 4,841 shares of the company’s stock valued at $1,088,000 after buying an additional 76 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock worth $17,790,912 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Barclays boosted their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Wells Fargo & Company raised their price objective on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Stock Performance

Shares of Cencora stock opened at $247.94 on Friday. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The firm has a market cap of $47.92 billion, a price-to-earnings ratio of 33.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49. The stock’s 50-day moving average is $239.01 and its 200-day moving average is $236.57. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.51% and a return on equity of 266.62%. Equities analysts predict that Cencora, Inc. will post 15.32 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s dividend payout ratio is 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.